1. Home
  2. JSPR vs SCYX Comparison

JSPR vs SCYX Comparison

Compare JSPR & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.66

Market Cap

34.7M

Sector

Health Care

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.92

Market Cap

41.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JSPR
SCYX
Founded
2018
1999
Country
United States
United States
Employees
64
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.7M
41.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
JSPR
SCYX
Price
$0.66
$0.92
Analyst Decision
Buy
Strong Buy
Analyst Count
11
1
Target Price
$15.50
$3.00
AVG Volume (30 Days)
371.6K
439.5K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$0.57
52 Week High
$7.19
$1.29

Technical Indicators

Market Signals
Indicator
JSPR
SCYX
Relative Strength Index (RSI) 16.03 58.48
Support Level N/A $0.68
Resistance Level $1.44 $0.96
Average True Range (ATR) 0.09 0.06
MACD -0.05 -0.00
Stochastic Oscillator 1.60 83.67

Price Performance

Historical Comparison
JSPR
SCYX

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: